MAP4K1 and lung cancer: Consistently, studies also demonstrated that mice that received adoptive transfer of MAP4K1 knockout T cells became resistant to lung cancer growth via mounting effective anti-tumor immune responses, suggesting that inhibition of MAP4K1 could be a viable approach for cancer immune therapy by promoting the effector functions of T cells [27].